CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults
Tonny Veenith, Benjamin A. Fisher, Daniel Slade, Anna Rowe, Rowena Sharpe, David R. Thickett, View ORCID ProfileTony Whitehouse, Matthew Rowland, James Scriven, Dhruv Parekh, Sarah J. Bowden, Joshua S. Savage, Duncan Richards, Julian Bion, Pamela Kearns, Simon Gates on behalf of CATALYST investigators
doi: https://doi.org/10.1101/2021.02.10.21251478
Tonny Veenith
1Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, United Kingdom
2Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
Benjamin A. Fisher
3Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
4National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
5Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Daniel Slade
5Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Anna Rowe
4National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
5Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Rowena Sharpe
5Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
David R. Thickett
2Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
6Department of Respiratory Medicine, University Hospitals Birmingham NHS Trust, UK
Tony Whitehouse
1Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, United Kingdom
2Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
Matthew Rowland
7Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK
James Scriven
8Department of Infectious Diseases, University Hospitals Birmingham NHS Trust, UK
Dhruv Parekh
1Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, United Kingdom
2Birmingham Acute Care Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, UK
6Department of Respiratory Medicine, University Hospitals Birmingham NHS Trust, UK
Sarah J. Bowden
5Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Joshua S. Savage
5Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Duncan Richards
9Oxford Clinical Trials Research Unit, Botnar Research Centre, University of Oxford, Oxford, UK
Julian Bion
1Department of Critical Care Medicine, University Hospitals Birmingham NHS Trust, United Kingdom
Pamela Kearns
4National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
5Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
Simon Gates
5Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Data Availability
This manuscript is for a clinical trial protocol. As such there are no data referred to in the manuscript.
Posted February 12, 2021.
CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults
Tonny Veenith, Benjamin A. Fisher, Daniel Slade, Anna Rowe, Rowena Sharpe, David R. Thickett, Tony Whitehouse, Matthew Rowland, James Scriven, Dhruv Parekh, Sarah J. Bowden, Joshua S. Savage, Duncan Richards, Julian Bion, Pamela Kearns, Simon Gates
medRxiv 2021.02.10.21251478; doi: https://doi.org/10.1101/2021.02.10.21251478
CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults
Tonny Veenith, Benjamin A. Fisher, Daniel Slade, Anna Rowe, Rowena Sharpe, David R. Thickett, Tony Whitehouse, Matthew Rowland, James Scriven, Dhruv Parekh, Sarah J. Bowden, Joshua S. Savage, Duncan Richards, Julian Bion, Pamela Kearns, Simon Gates
medRxiv 2021.02.10.21251478; doi: https://doi.org/10.1101/2021.02.10.21251478
Subject Area
Subject Areas
- Addiction Medicine (346)
- Allergy and Immunology (666)
- Anesthesia (181)
- Cardiovascular Medicine (2636)
- Dermatology (223)
- Emergency Medicine (398)
- Epidemiology (12206)
- Forensic Medicine (10)
- Gastroenterology (756)
- Genetic and Genomic Medicine (4081)
- Geriatric Medicine (387)
- Health Economics (679)
- Health Informatics (2639)
- Health Policy (1002)
- Hematology (362)
- HIV/AIDS (849)
- Medical Education (399)
- Medical Ethics (109)
- Nephrology (433)
- Neurology (3861)
- Nursing (209)
- Nutrition (575)
- Oncology (2017)
- Ophthalmology (584)
- Orthopedics (240)
- Otolaryngology (304)
- Pain Medicine (250)
- Palliative Medicine (75)
- Pathology (472)
- Pediatrics (1113)
- Primary Care Research (450)
- Public and Global Health (6512)
- Radiology and Imaging (1396)
- Respiratory Medicine (871)
- Rheumatology (403)
- Sports Medicine (342)
- Surgery (442)
- Toxicology (52)
- Transplantation (185)
- Urology (165)